<DOC>
	<DOCNO>NCT01046630</DOCNO>
	<brief_summary>The purpose study determine effect single dose infusion AZD 6765 compare placebo ketamine blood oxygen level dependent signal use fMRI ( functional Magnetic Resonance Imaging ) depress subject .</brief_summary>
	<brief_title>Study Where Pharmaco Magnetic Resonance Imaging ( MRI ) Effects AZD6765 Will Compared Placebo Depressive Male Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ketamine</mesh_term>
	<criteria>Documented clinical diagnosis meeting criterion DSMIV structure clinical interview , major depressive disorder , single episode recurrent Outpatient status screen randomisation A major depression disorder major impact subject current psychiatric status Subjects allow use mood stabilizer , antidepressant antipsychotic psychoactive drug Subjects lifetime history schizophrenia , bipolar , psychosis psychotic depression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Phase I</keyword>
	<keyword>BOLD signal</keyword>
	<keyword>fMRI</keyword>
	<keyword>AZD6765</keyword>
	<keyword>BOLD signal measure fMRI</keyword>
</DOC>